Key Points
- Tempus AI Director Nadja West sold 3,000 shares at an average price of $69, generating $207,000. The Rule 10b5-1 transaction reduced her direct holdings by 8.58% to 31,981 shares.
- Tempus AI recently exceeded quarterly earnings expectations, reporting a loss of $0.04 per share versus the expected $0.14 loss and revenue of $382.49 million, up 21.6% year over year.
- Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $67.23; the stock recently opened at $62.27 and has a 52-week range of $40.77 to $104.32.
Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) Director Nadja West sold 3,000 shares of the business's stock in a transaction on Friday, August 28th. The stock was sold at an average price of $69.00, for a total transaction of $207,000.00. Following the completion of the sale, the director directly owned 31,981 shares of the company's stock, valued at approximately $2,206,689. The trade was a 8.58% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Tempus AI Stock Performance
TEM opened at $62.27 on Wednesday. The firm's fifty day simple moving average is $55.21 and its two-hundred day simple moving average is $51.87. Tempus AI, Inc. has a 52-week low of $40.77 and a 52-week high of $104.32. The company has a market cap of $11.24 billion, a price-to-earnings ratio of -43.24 and a beta of 3.71. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06.
Tempus AI (NASDAQ:TEM - Get Free Report) last released its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business had revenue of $382.49 million during the quarter, compared to analysts' expectations of $379.69 million. During the same quarter in the previous year, the company earned ($0.22) earnings per share. The company's quarterly revenue was up 21.6% on a year-over-year basis. Equities analysts anticipate that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Tempus AI
Several institutional investors have recently added to or reduced their stakes in the business. JPL Wealth Management LLC purchased a new stake in shares of Tempus AI during the 3rd quarter worth approximately $26,000. Los Angeles Capital Management LLC purchased a new stake in shares of Tempus AI in the fourth quarter valued at about $27,000. EMC Capital Management purchased a new stake in Tempus AI during the 2nd quarter valued at approximately $29,000. Harvest Fund Management Co. Ltd acquired a new position in shares of Tempus AI in the third quarter valued at approximately $38,000. Finally, Whittier Trust Co. raised its stake in shares of Tempus AI by 190.0% during the first quarter. Whittier Trust Co. now owns 870 shares of the company's stock worth $41,000 after purchasing an additional 570 shares during the last quarter. Hedge funds and other institutional investors own 24.22% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the company. Lake Street Capital lowered Tempus AI to a "hold" rating in a research report on Monday, July 20th. TD Cowen restated a "buy" rating on shares of Tempus AI in a report on Wednesday, July 15th. Wolfe Research assumed coverage on Tempus AI in a report on Tuesday, June 2nd. They set a "peer perform" rating for the company. Freedom Capital raised shares of Tempus AI to a "hold" rating in a research note on Tuesday, June 30th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $75.00 target price on shares of Tempus AI in a report on Friday, July 31st. Ten research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, Tempus AI presently has a consensus rating of "Hold" and an average price target of $67.23.
Read Our Latest Research Report on Tempus AI
Tempus AI Company Profile
(
Get Free Report)
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
